Market News / Story
Ribo Files EU CTA for Phase I of INHBE siRNA RBD3133
·
Ribo submitted a European clinical trial application for a Phase I study of RBD3133, an INHBE‑targeting siRNA. Material Details #DetailAI Analyst View1EU CTA filed for RBD3133 Phase IRegulatory step enabling first‑in‑human testing; advances pipeline toward potential value inflection.2Target: INHBE via siRNANew target/modality could open therapeutic options; success may broaden platform value. Context by AI Analyst This is an early-stage regulatory milestone signaling…